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OBJECTIVES: To identify hypertension prescription patterns in
a Los Angeles County Latino population, evaluate prevalence of
use of foreign antihypertensive drugs, and its association with
blood pressure control. METHODS: Data was obtained from
the Los Angeles Latino Eye Study (LALES), a study designed to
assess the prevalence of eye disease and self-reported visual func-
tion in Latinos age 40 and older. In total, 1076 patients with self-
reported history of hypertension, clinic blood pressure values
and available medication proﬁle of drugs taken within the past
month were identiﬁed for analysis. Antihypertensive drugs were
identiﬁed and assessed for origin as US or foreign (Mexican,
Central or South American), drug class, and total number of
antihypertensives used. Chi-square tests were used to test for dif-
ferences between US and foreign drug groups in terms of uti-
lization of different drug classes, demographic differences, and
blood pressure control. RESULTS: Only 50.5% (533/1076) of
subjects with history of hypertension were on at least one anti-
hypertensive medication. 34.9% of subjects had taken two or
more antihypertensives in the past month. A total of 30.2%
(161/533) had taken a beta-blocker within the previous month,
32.8% (175/533) an ACE-inhibitor, and 25.0% (133/533) a
calcium channel blocker. The prevalence of foreign and US sup-
plied drug use were 1.5% (16/1076) and 48.0% (517/1076)
respectively. The difference in blood pressure control between the
US and foreign drug use groups was not statistically signiﬁcant
(p = 0.1160). CONCLUSIONS: Although foreign medications
may be easily accessible, there does not appear to be signiﬁcant
use of foreign antihypertensive medications within this Los
Angeles Latino population. The relationship between foreign
drug use and blood pressure control was not found to be statis-
tically signiﬁcant but the result may be due to the limited number
of foreign drug use observations.
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OBJECTIVES: To assess type, duration, and medication avail-
ability of antihypertensive therapy among veterans. METHODS:
Electronic medical records from the Central Texas Veterans
Health Care System were extracted for adults newly diagnosed
with hypertension between 1995 and 2003. Information on
demographic (age, gender, and race/ethnicity) and clinical (diag-
noses, height, weight, labs, and blood pressure values) charac-
teristics were collected. Drug utilization was measured as a
time-dependent variable; thus, the use of combination therapies
was captured for any given day for each patient in the sample.
Medication availability was calculated as the ratio of “total days
supply” and “number of days between ﬁrst and last reﬁll.”
RESULTS: The average age of the participants (N = 11,187) was
60.7 (SD: 12.7). Half (50.1%) of the patients could be catego-
rized as having controlled blood pressure. Veterans were fol-
lowed for an average of 3.6 years (total of 51,549 person-years).
Overall, 29,561 treatment episodes were identiﬁed; an average
of about 2.6 per patient. Over forty percent (41.6%) of these
episodes involved one medication only, but patients frequently
used dual (26.9%) and three or more (15.9%) combination ther-
apies. Patients took “single therapy alone” for a median of 1.3
years, “dual therapies alone” for a median of 1.0 years, whereas
“three or more therapies” for a median of 0.9 years. Medication
availability ratios were relatively high, ranging from 0.88 to
0.93. Overall, calcium channel blockers (22.4%), angiotensin
converting enzyme inhibitors (21.4%), and beta-blockers
(19.9%) were used most frequently. CONCLUSIONS: Our
results indicate high medication availability ratios; i.e., veterans
ﬁlled their antihypertensive medications as it was prescribed 
by their physicians. Nevertheless, the average blood pressure
control rate was only 50 percent, which requires improvements
in patients’ antihypertensive therapy. The necessity of better
selection of antihypertensive therapies is also supported by the
ﬁnding of frequent therapy changes.
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OBJECTIVES: Despite inherent limitations, administrative
claims databases have been widely used to assess quality of care
and evaluate medical care appropriateness in several therapeutic
areas including hypertension (HTN). The objective of this study
was to assess the validity of two commonly used claims-based
algorithms in identifying the presence of HTN, using patient
medical records (MR) as the gold standard. METHODS:
Managed care claims data spanning January 1, 2000 through
March 31, 2003 were used. HTN patients (test-positives) were
identiﬁed using two algorithms—algorithm A used medical
claims only and algorithm B used both pharmacy and medical
claims. Test-positives and test-negatives (health plan members
without HTN medical claims in algorithm A and without a HTN
medical AND pharmacy claim in algorithm B) were 1 :1 matched
on their propensity for having a HTN claim. Propensity scores
were computed using a logistic regression model including demo-
graphic, clinical and physician characteristics to allow for mul-
tivariate matching. MR were reviewed for the presence of HTN,
and the validity of claims-based criterion was evaluated by com-
puting its sensitivity and speciﬁcity, and comparing with MR
data. RESULTS: A total of 258 and 138 matched pairs of test-
positives and test-negatives for algorithms A and B, respectively,
were identiﬁed. Baseline characteristics were similar for test-pos-
itives and test-negatives. The sensitivity (95% CI) and speciﬁcity
(95% CI) of algorithm A were calculated as 71% (65.1–76.1)
and 75% (68.8–80.3) respectively, and those of algorithm B were
76% (69.1–82.3) and 93.3 (86.6–97.3) respectively. The kappa
score for assessing strength of agreement between claims data
and MR was 0.45 for algorithm A and 0.65 for algorithm B.
CONCLUSION: The results demonstrate the validity of using
claims based algorithms in identifying hypertensive patients.
However, the higher sensitivity and speciﬁcity of algorithm B
demonstrate that using a combination of medical and pharmacy
claims will help reduce the risk of patient misclassiﬁcation, when
compared with using medical claims only.
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OBJECTIVE: To assess the advantages and limitations of using
a web-based survey to obtain patient-reported outcomes (PRO).
METHODS: A web-based patient survey was conducted in a
population diagnosed with hypertension to assess the correlation
between blood pressure control and patients’ satisfaction with
antihypertensive treatment. Patients were selected from the
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Chronic Illness Panel, a group of more than two-million indi-
viduals who agreed to participate in surveys conducted by Harris
Interactive Service Bureau. Patients selected had a self-reported
diagnosis of hypertension and were receiving antihypertensive
medication. Questions assessed patients’ antihypertensive med-
ication class, blood pressure before and after initiation of the
medication, improvement in health status related to treatment,
and patients’ overall satisfaction with medication. RESULTS:
Using a web-based patient survey has several advantages. It pro-
vided a quick turn-around time as pilot testing and revising the
questionnaire were completed within a week, with full ﬁelding
of the survey accomplished in two-weeks. Because of the prior
consent, the study bypassed the sometimes lengthy approval
process by an Investigational Review Board. The direct entry of
the data by patients saved time and avoided errors from data
entry by a secondary person. The overall cost of the study was
lower than traditional mailing survey. A majority of missing data
occurred in questions related to patients’ recall of blood pressure
measurements. Data was mostly complete for questions with
subjective answers such as overall satisfaction. The limitations
of the web-based survey method included generalizability and
accuracy of recalled information. CONCLUSIONS: Using a
web-based survey is recommended for obtaining PRO in a timely
manner and at a low cost. However, the information should be
interpreted with care. The study subjects were from a select
group that may render selection bias. In addition, recalled infor-
mation seems difﬁcult to obtain and if reported, its accuracy may
be uncertain.
CARDIOVASCULAR DISEASE—Myocardial Infarction
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OBJECTIVE: Because of the difﬁculty of early Venous Throm-
boembolism (VTE) diagnosis and the serious consequences of the
disease, prophylaxis is routinely indicated in medical at-risk
patients. This study examines the effect of VTE prophylaxis by
examining rate of secondary diagnosis of VTE in myocardial
infarction patients and its impact on overall costs of in-patient
care in order to optimize drug prophylaxis. METHODS: An
administrative database of 720,982 discharges containing ICD-
9-CM coding and other data from hospitals across the US was
analyzed. Study patients had a principal diagnosis of myocardial
infarction, and were prescribed heparin or enoxaparin. Associa-
tions between age, gender, length of stay (LOS), number of 
secondary diagnoses (NSD), drug, in-hospital deaths, overall
hospital costs, and incidence of VTE were studied using logistic
regression. RESULTS: From 8694 patients who met the inclu-
sion criteria, 35 patients (0.40%; two enoxaparin vs. 33 heparin)
showed a secondary diagnosis of VTE. Overall mean hospital
costs (p < 0.0001; OR = 2.685) were found to be signiﬁcantly
different between patients showing a secondary diagnosis of VTE
($30,617.4) and those who did not ($15,689.0). However, when
signiﬁcant clinical and demographic factors were controlled for
like LOS (p < 0.0001; OR = 1.053), in-hospital deaths (p =
0.0121; OR = 3.099), NSD (p < 0.0001; OR = 1.410), and age
(p = 0.0027; OR = 1.041), overall hospital costs were not found
to be signiﬁcantly different (p = 0.4459; OR = 1.255). In patients
who showed a secondary diagnosis of VTE, heparin prescribed
patients incurred higher mean overall hospital costs than enoxa-
parin patients; p < 0.0001 ($31,799.6 vs. $11,112.1), possibly
due to a longer LOS (11.4 days vs. 5.5 days). CONCLUSIONS:
The most cost-effective strategy in this analysis was VTE pre-
vention and enoxaparin was a cost-effective treatment choice.
Rational and adequate VTE prophylaxis needs to be addressed
along with further research on administrative database coding
and documentation issues in order to more fully explore the
application of these ﬁndings for a clinician.
PCV51
SHORT AND LONG-TERM COST-EFFECTIVENESS OF EARLY
AND SUSTAINED DUAL ORAL ANTIPLATELET THERAPY
WITH CLOPIDROGREL FOLLOWING PERCUTANEOUS
CORONARY INTERVENTION:A CANADIAN ECONOMIC
ANALYSIS
Kolm P1,Veledar E1, Forte L2,Amin M3, Bouin O4, Jackson J5,
Gabriel S4,Weintraub WS1
1Emory University, Atlanta, GA, USA; 2Sanoﬁ-Synthelabo, Markham,
ON, Canada; 3Bristol-Myers Squibb, St Laurent, QC, Canada;
4Sanoﬁ-Aventis, Bagneux, France; 5Bristol-Myers Squibb Company,
Princeton, NJ, USA
OBJECTIVES: Results from the pivotal Clopidogrel for the
Reduction of Events During Observation (CREDO) trial demon-
strated that one year of clopidogrel following a percutaneous
coronary intervention (PCI) signiﬁcantly reduced the absolute
combined risk of death, MI, or stroke by 3%. Utilizing 
Canadian Case Mix Group (CMG) costing, we sought to deter-
mine the incremental cost-effectiveness per event prevented over
one-year and estimate the incremental cost-effectiveness per life
year gained (LYG) for a clopidogrel + ASA strategy vs. ASA alone
before and after PCI. METHODS: Canadian health care
resource utilization costs were obtained from Case Mix Group
costing from the 2003 Health Funding and Costing Branch of
Alberta Health and Wellness Report. Cost-effectiveness was
expressed as the incremental cost per event prevented (ICERep)
or cost per life year gained (ICERlyg). Bootstrap methods were
used to estimate the joint distribution of cost and effectiveness
differences between the two arms and obtain 95% conﬁdence
intervals (CI). The Canadian costs of clopidogrel and aspirin
were C$2.40 per 75mg, and C$0.05 per tablet respectively. Life
expectancy in trial survivors was estimated from discounted
Framingham and Saskatchewan data. RESULTS: Total one-year
average cost per patient in clopidrogrel + ASA and ASA alone
arms were C$21,241 and C$20,786 respectively; a difference 
of C$455 (95% CI = -C$495 to C$1391). The ICERep was
C$15,040 with 59% of bootstrapped ICERs less than C$20,000
(87% less than C$50,000). The ICERlyg using Framingham esti-
mates was C$2980 with over 96% of bootstrapped ICERs less
than C$20,000 (98% less than C$50,000). The ICERlyg using
Saskatchewan estimates was C$2369 with over 97% of boot-
strapped ICERs less than C$20,000 (nearly 99% less than
C$50,000). CONCLUSION: Treatment with clopidogrel for 12-
months following PCI is highly cost-effective in the Canadian
health care system.
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Patients who survive an acute myocardial infarction (MI) are at
increased risk of subsequent major cardiovascular events and
